Marie Duhamel
-
Associate Professor
Dr. Marie Duhamel is an Associate Professor within the PRISM Laboratory (Inserm Unit 1192) at the University of Lille, a position she has held since 2018. Her research focuses on the interplay between macrophages and cancer, with a particular emphasis on harnessing immunotherapeutic approaches. Dr. Duhamel has authored 25 research articles (including 11 as first or last author), 2 reviews, and 6 conference proceedings. She also holds a patent (PCT/FR2024/050238) related to Furin-inhibited CAR macrophages, which serves as the foundation for the CARMA project, currently in incubation since 2024. She has secured four grants as principal investigator, notably the current ANR-funded ICARE project, which aims to develop universal antigens for CAR therapies, and the PLBIO project, focusing on the surface ghost proteome of triple-negative breast cancers. These efforts are directed toward identifying novel therapeutic targets and improving the efficacy of immunotherapies.
Dr. Duhamel’s contributions to science have been recognized with several awards, including the Thesis Award from the French Society of Electrophoresis and Protein Analysis in 2017, along with several conference awards.
Beyond her research, Dr. Duhamel is involved in scientific governance and community building. She co-manages the OrganOmics platform and served as a member of the local organizing committee for the SMAP congress held in Lille in 2024. From 2020 to 2023, she was a member of the board of directors of the French Society of Proteomics, where she also served as Editor-in-Chief of the quarterly magazine. She is also member of the GDR organoid network. Dr. Duhamel is also involved in the supervision of PhD students (3) and master’s students (10 since 2018).
- https://orcid.org/0000-0002-4006-5605
- https://www.linkedin.com/in/marie-duhamel-7a3aa959/?originalSubdomain=fr
1. Leroy M, Aumar M, Duhamel M, Dauchet L, Figeac M, Gaillard S, Hankard R, Labreuche J, Marot G, Reversat J, Armand V, Salzet M, Sfeir R, Vandel J, Gottrand F. Long-term outcome of oesophageal atresia in adolescence (TransEAsome): a national French cohort study protocol. BMJ Open. 2025 Jan 11;15(1):e086303. doi: 10.1136/bmjopen-2024-086303.
2. Raffo-Romero A, Ziane Chaouche L, Hajjaji N, Salzet M, Duhamel M. Protocol for generating a co-culture method of macrophages with breast cancer tumoroids. STAR Protoc. 2024 Dec 20;6(1):103536. doi: 10.1016/j.xpro.2024.103536.
3. Ziane Chaouche L, Raffo-Romero A, Hajjaji N, Kobeissy F, Pinheiro D, Aboulouard D, Cozzani A, Mitra S, Fournier I, Cizkova D, Salzet M, Duhamel M. Inhibition of furin in CAR macrophages directs them toward a proinflammatory phenotype and enhances their antitumor activities. Cell Death Dis. 2024 Dec 4;15(12):879. doi: 10.1038/s41419-024-07267-4.
4. Raffo-Romero A, Ziane Chaouche L, Salomé-Desnoulez S, Hajjaji N, Fournier I, Salzet M, Duhamel M. A co-culture system of macrophages with breast cancer tumoroids to study cell interactions and therapeutic responses. Cell Rep Methods. 2024 Jun 17;4(6):100792. doi: 10.1016/j.crmeth.2024.100792.
5. Zirem Y, Ledoux L, Roussel L, Maurage CA, Tirilly P, Le Rhun E, Meresse B, Yagnik G, Lim M, Rothschild K, Duhamel M, Salzet M, Fournier I. Real-time Glioblastoma Tumor MicroEnvironment Assessment by SpiderMass for Improved Patient Management. Cell Rep Med. 2024 Apr 16;5(4):101482. doi: 10.1016/j.xcrm.2024.101482.
6. Wisztorski M*, Aboulouard S*, Roussel L*, Duhamel M*, Saudemont P, Cardon T, Narducci F, Robin YM, Lemaire AS, Bertin D, Hajjaji N, Kobeissy F, Leblanc E, Fournier I, Salzet M.Fallopian tube lesions as potential precursors of early ovarian cancer: a comprehensive proteomic analysis. Cell Death Dis. 2023 Sep 30;14(9):644. doi: 10.1038/s41419-023-06165-5
7. Capuz A, Osien S, Cardon T, Karnoub MA, Aboulouard S, Raffo-Romero A, Duhamel M, Cizkova D, Trerotola M, Devos D, Kobeissy F, Vanden Abeele F, Bonnefond A, Fournier I, Rodet F, Salzet M. Heimdall, an alternative protein issued from a ncRNA related to kappa light chain variable region of immunoglobulins from astrocytes: a new player in neural proteome. Cell Death Dis. 2023 Aug 16;14(8):526. doi: 10.1038/s41419-023-06037-y.
8. Capuz A, Osien S, Karnoub MA, Aboulouard S, Laurent E, Coyaud E, Raffo-Romero A, Duhamel M, Bonnefond A, Derhourhi M, Trerotola M, El Yazidi-Belkoura I, Devos D, Zilkova M, Kobeissy F, Vanden Abeele F, Fournier I, Cizkova D, Rodet F, Salzet M. Astrocytes express aberrant immunoglobulins as putative gatekeeper of astrocytes to neuronal progenitor conversion. Cell Death Dis. 2023 Apr 4;14(4):237. doi: 10.1038/s41419-023-05737-9.
9. Raffo-Romero A, Aboulouard S, Bouchaert E, Rybicka A, Tierny D, Hajjaji N, Fournier I, Salzet M, Duhamel M. Establishment and characterization of a tumoroid biobank derived from dog patient’s mammary tumors for translational research. BMC Biol. 2023 Feb 3;21(1):23. doi: 10.1186/s12915-023-01516-2.
10. Hua Y, Vella G, Rambow F, Allen E, Martinez AA, Duhamel M, Junius S, Smeets A, Nottner D, Laoui D, Dimmeler S, Hehlgans T, Liston A, Floris G, Lambrechts D, Merchiers P, Bosisio FM, Marine JC, Schlenner S, Bergers G. Cancer immunotherapies transition postcapillary venules into high-endothelial venules that generate TCFI+T lymphocyte niches through a feed-forward loop. Cancer Cell. 2022 Dec 12;40(12):1600-1618.e10. doi: 10.1016/j.ccell.2022.11.002.
11. Duhamel M*, Drelich L*, Wisztorski M*, Aboulouard S, Gimeno JP, Ogrinc N, Devos P, Cardon T, Weller M, Escande F, Zairi F, Maurage CA, Le Rhun E, Fournier I, Salzet M. Spatial analysis of the glioblastoma proteome reveals specific molecular signatures and markers of survival. Nat Commun. 2022 Nov 4;13(1):6665. doi: 10.1038/s41467-022-34208-6.
12. Rose M*, Duhamel M*, Aboulouard S, Kobeissy F, Tierny D, Fournier I, Rodet F, Salzet M. Therapeutic anti-glioma effect of the combined action of PCSK inhibitor with the anti-tumoral factors secreted by Poly(I:C)-stimulated macrophages. Cancer Gene Ther. 2022 Jan;29(1):22-36. doi: 10.1038/s41417-020-00286-1.
13. Rose M, Cardon T, Aboulouard S, Hajjaji N, Kobeissy F, Duhamel M, Fournier I, Salzet M. Surfaceome proteomic of glioblastoma revealed potential targets for immunotherapy. Front Immunol. 2021 Sep 27:12:746168. doi: 10.3389/fimmu.2021.746168.
14. Aboulouard S*, Wisztorski M*, Duhamel M, Saudemont P, Cardon T, Narducci F, Lemaire AS, Kobeissy F, Leblanc E, Fournier I, Salzet M. In-depth proteomics analysis of sentinel lymph nodes from individuals with endometrial cancer. Cell Rep Med. 2021 Jun 15;2(6):100318. doi: 10.1016/j.xcrm.2021.100318.
15. Rose M, Duhamel M, Rodet F, Salzet M. The Role of Proprotein Convertases in the Regulation of the Function of Immune cells in the Oncoimmune Response. Front Immunol. 2021 Apr 29:12:667850. doi: 10.3389/fimmu.2021.667850.
16. Cardon T, Ozcan B, Aboulouard S, Kobeissy F, Duhamel M, Rodet F, Fournier I, Salzet M. Epigenetic studies revealed a ghost proteome in PC1/3 KD macrophages under anti-tumoral resistance induced by IL-10. ACS Omega. 2020 Oct 1;5(43):27774-27782. doi: 10.1021/acsomega.0c02530.
17. Lemaire Q, Duhamel M, Raffo-Romero A, Salzet M, Lefebvre C. Characterization of immune cell-derived extracellular vesicles: functional impact on cell environment. J Vis Exp. 2020 Jun 2:(160). doi: 10.3791/60118.
18. Murgoci AN, Cardon T, Aboulouard S, Duhamel M, Fournier I, Cizkova D, Salzet M. Reference and Ghost Proteins Identification in Rat C6 Glioma Extracellular Vesicles. iScience. 2020 May 22;23(5):101045. doi: 10.1016/j.isci.2020.101045.
19. Rose M*, Duhamel M*, Aboulouard S, Kobeissy F, Le Rhun E, Desmons A, Tierny D, Fournier I, Rodet F, Salzet M. The role of a proprotein convertases inhibitor in reactivation of tumor associated macrophages and inhibition of glioma growth. Mol Ther Oncolytics. 2020 Mar 31:17:31-46. doi: 10.1016/j.omto.2020.03.005.
20. Murgoci AN*, Duhamel M*, Raffo-Romero A, Mallah K, Aboulouard S, Lefebvre C, Kobeissy F, Fournier I, Zilkova M, Maderova D, Cizek M, Cizkova D, Salzet M. Location of neonatal microglia drives small extracellular vesicles content and biological functions in vitro. J Extracell Vesicles. 2020 Feb 18;9(1):1727637. doi: 10.1080/20013078.2020.1727637.
21. Rodet F, Capuz A, Ozcan BA, Le Beillan R, Raffo-Romero A, Kobeissy F, Duhamel M, Salzet M. PC1/3 KD macrophages exhibit resistance to the inhibitory effect of IL-10 and a higher TLR4 activation rate, leading to an anti-tumoral phenotype. Cells. 8(12): 1490 (2019)
22. Rodet F, Capuz A, Hara T, van Meel R, Duhamel M, Rose M, Raffo-Romero A, Fournier I, Salzet M. Deciphering molecular consequences of the proprotein convertase 1/3 inhibition in macrophages for application in anti-tumour immunotherapy. J Biotechnol. 20; 282:80-85. (2018)
23. Fatou B, Saudemont P, Duhamel M, Ziskind M, Focsa C, Salzet M, Fournier I. Real time and in vivo pharmaceutical and environmental studies with SpiderMass instrument. J Biotechnol. 281: 61-66. (2018)
24. Duhamel M*, Rose M*, Rodet F, Murgoci A.N, Zografidou L, Régnier-Vigouroux A, Vanden Abeele F, Kobeissy F, Nataf S, Pays L, Wisztorski M, Fournier I, Salzet M. Paclitaxel treatment and PC1/3 knockdown in macrophages is a promising anti-glioma strategy as revealed by proteomics and cytotoxicity studies. Molecular and Cellular Proteomics. 17(6): 1126-1143 (2018)
25. Le Rhun E*, Duhamel M*, Wisztorski M, Gimeno JP, Zairi F, Escande F, Reyns N, Kobeissy F, Maurage CA, Salzet M, Fournier I. Evaluation of Non-Supervised MALDI Mass Spectrometry Imaging Combined with MicroProteomics for Glioma Grade III Classification. Biochim Biophys Acta Proteins Proteom. 1865(7):875-890 (2017).
26. Duhamel M*, Rodet F*, Murgoci A, Desjardins R, Gagnon H, Wisztorski M, Fournier I, Day R, Salzet M. The proprotein convertase PC1/3 regulates TLR9 trafficking and the associated signaling pathways. Scientific Reports. 6, 19360 (2016).
27. Duhamel M, Rodet F, Delhem N, Vanden Abeele F, Kobeissy F, Nataf S, Pays L, Desjardins R, Gagnon H, Wisztorski M, Fournier I, Day R, Salzet M. Molecular Consequences of Proprotein Convertase 1/3 (PC1/3) Inhibition in Macrophages for Application to Cancer Immunotherapy: A Proteomic Study. Molecular and Cellular Proteomics. 14, 2857–77 (2015).